Replies to post #7773 on Aurinia Pharmaceuticals Inc (AUPH)

[Lunacy_John Galt]

I think there's a 90%+ chance the PR states Aurinia announces positive top-line results from their Ph2 DES trial for VOS vs. Restasis. The primary endpoint is tolerability vs. restasis, so this should be a slam dunk given everything we know and have heard from the company. The secondary endpoints are what will determine the value of VOS IMO. I'm optimistic about the secondary endpoints as well based on what they've learned from the ph1 and Merck animal trials. Really the only thing I'm unsure on is if the 30 day trial was long enough to show efficacy, but given that restasis takes months to show efficacy this was a smart trial design.

On the other hand, I have no idea how the investment world will respond. Could easily be a sell the news event, PPS spike, or delayed price appreciation depending on what the shorts have up their sleeves.